Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

January 31, 2024

Conditions

Adult Solid Tumor

Interventions

DRUG

HLX26

Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

DRUG

HLX10

Humanized Anti-Programmed Death-1 Monoclonal Antibody

Trial Locations (1)

Xuzhou Central Hospital, Xuzhou

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY